SERAHealthcare · Medical Devices

SERA Stock Forecast: Sera Prognostics, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026

$2.04

−0.97% on the day

The 4 Wall Street analysts covering Sera Prognostics, Inc. hold a median 12-month price target of $5.5 — +169.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 31 Oct 2026 — in the lower half.

Market cap

$80.5M

Ticker Nerd rank

43/ 100

Median analyst target

$5.50

Analysts covering

Revenue$30K+76.5% y/y

Operating income−$10.0M

Net income−$9.1M

Free cash flow−$6.4M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+0.5%

−2.4%

YTD

−30.8%

−39.1%

From 52W high

−44.7%

From 52W low

+28.3%

$1.59

$3.69

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

SERA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sera Prognostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026

43/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Growth

Revisions

Momentum

Quality

Volatility

Issuance

Value

Size (75): Smaller than most of the companies we track.

Value (17): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SERA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SERA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts

4 Buy0 Hold0 Sell

Low $5.00Median $5.50High $6.00

The green dot is the last close — the median target sits +169.6% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
4 June 2026	Craig-Hallum	Initiates	Buy	$6.00
10 Aug 2023	Citigroup	Maintains	Neutral	—
10 Nov 2022	Citigroup	Maintains	Neutral	—
14 Sept 2022	Berenberg	Initiates	Buy	—
29 Aug 2022	Oppenheimer	Maintains	Outperform	—
27 Apr 2022	Berenberg	Initiates	Buy	—
30 Mar 2022	Citigroup	Downgrade	Neutral	—
19 Nov 2021	Oppenheimer	Initiates	Outperform	—
9 Aug 2021	Citigroup	Initiates	Buy	—
9 Aug 2021	Cowen & Co.	Initiates	Outperform	—
9 Aug 2021	William Blair	Initiates	Outperform	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SERA appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

SERA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Sera Prognostics, Inc. returned −39.1% against +12.4% for the S&P 500, dividends included.

SERA vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SERA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year

Analysts raising

Analysts cutting

Fundamentals

Sera Prognostics, Inc. (SERA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −3.1×
Price / sales: 1149.7×
Price / book: 1.4×
EV / EBITDA: −1.0×

Growth & margins

Revenue growth (YoY): 76.5%
Earnings growth (YoY): 76.5%
Gross margin: −66.7%
Operating margin: −33346.7%
Net margin: −102.5%

Returns & dividend

Return on equity: −45.0%
Return on assets: −23.5%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sera Prognostics, Inc. (SERA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Sera Prognostics, Inc. has a market value of $80.5M and an enterprise value of $37.0M.
Revenue in the twelve months to 30 June 2026: $70K. The latest quarter grew 76.5% year on year.
Net income over the same four quarters: −$33.2M, a −47475.7% net margin.
Diluted earnings per share, trailing twelve months: $−0.67.
Free cash flow in the twelve months to 30 June 2026: −$28.2M.
Shares outstanding: 39.4M.
Trailing P/E: −3.1×; forward P/E: −3.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Sera Prognostics, Inc. employs 71 people — $985.9 of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

SERA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
SERASera Prognostics, Inc.	$80.5M	43
LUCDLucid Diagnostics, Inc.	$82.2M	36
HYPRHyperfine, Inc.	$76.1M	47
OMOutset Medical, Inc.	$73.7M	38
MBOTMicrobot Medical, Inc.	$73.2M	12
LNSRLENSAR, Inc.	$71.7M	56
ECORelectroCore, Inc.	$67.8M	50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sera Prognostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SERA news & analysis

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026

PRNewsWire · 21 Oct 2026neutral

Sera Prognostics said it will report its third-quarter fiscal 2026 financial results after market close on November 4, 2026. A conference call and live webcast to discuss operational highlights, financial results and key topics is scheduled for 5:00 p.m.

Why it matters — SERA watchers can note the date and time of the company's upcoming results discussion.

1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.

PRNewsWire · 25 Aug 2026positive

A leading OB-GYN, Dr. Thaïs Aliabadi, highlights that preterm birth risk can be identified between weeks 18 and 21 of pregnancy, pointing to Sera Prognostics' PreTRM blood test and PRIME trial results showing early, low-cost intervention can reduce the earliest preterm births by more than half.

Why it matters — The piece spotlights the PreTRM test and favorable PRIME trial data, raising awareness of Sera Prognostics' product among expectant mothers and clinicians.

SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER

PRNewsWire · 19 Aug 2026positive

Sera Prognostics, Inc. announced on August 19, 2026 that Scott Gleason has been appointed Chief Financial Officer, effective August 31, 2026. Gleason brings over 25 years of experience in healthcare, diagnostics, and capital markets to the company.

Why it matters — A new CFO with extensive healthcare and capital markets experience could be significant for SERA watchers given the company's focus on pregnancy biomarker diagnostics and its standing as a publicly traded firm.

Sera Prognostics Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026neutral

Sera Prognostics reported modest second-quarter revenue and discussed progress on payer engagement, Illinois Medicaid policy, clinical evidence, and European regulatory preparations for its PreTRM Test-guided care platform.

Why it matters — SERA watchers would care because the update offers insight into the company's operational milestones and market-access strategy for its core PreTRM test.

Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Sera Prognostics, Inc. held its Q2 2026 earnings call, and a transcript of the call has been published by Seeking Alpha. The event covers the company's second-quarter 2026 financial results and management commentary.

Why it matters — A SERA watcher would care because the earnings call transcript provides a record of the company's latest quarterly financial performance and management's discussion of its business.

FAQ

Frequently asked questions about SERA stock

What is the SERA stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Sera Prognostics, Inc. have a median 12-month price target of $5.5, with estimates ranging from $5 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SERA stock a buy right now?

Of the 4 analysts covering Sera Prognostics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sera Prognostics, Inc. 43 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SERA?

As at 31 Oct 2026, Sera Prognostics, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (75 of 100).

Will SERA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +169.6% from the last close, and Ticker Nerd's factor model ranks Sera Prognostics, Inc. 43 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SERA stock forecast for 2030?

No analyst covering Sera Prognostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SERA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $6 over the next 12 months.

How has SERA stock performed over the past year?

Sera Prognostics, Inc. returned -39.1% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sera Prognostics, Inc. do?

Sera Prognostics, Inc. Class A Common Stock represents ownership in Sera Prognostics, a women’s health diagnostics company focused on improving maternal and neonatal care.

What is the latest news on SERA?

The most recent item we track (PRNewsWire, 21 Oct 2026): "SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026". Sera Prognostics said it will report its third-quarter fiscal 2026 financial results after market close on November 4, 2026. A conference call and live webcast to discuss operational highlights, financial results and key topics is scheduled for 5:00 p.m.

Company

About Sera Prognostics, Inc.

Sera Prognostics, Inc. Class A Common Stock represents ownership in Sera Prognostics, a women’s health diagnostics company focused on improving maternal and neonatal care. The company develops and commercializes blood-based biomarker tests and predictive analytics designed to help physicians assess pregnancy-related risks, with its flagship PreTRM test used to estimate the risk of spontaneous preterm birth in singleton pregnancies. Sera Prognostics applies proteomics and bioinformatics to identify clinically useful markers from blood samples, supporting earlier risk awareness in prenatal care. Its product and service portfolio centers on pregnancy biomarker discovery, test validation, and diagnostic reporting for healthcare providers in the United States. Headquartered in Salt Lake City, Utah, and founded in 2008, Sera Prognostics operates as a specialized medical diagnostics business serving the broader women’s health and precision medicine markets.

CEO Ms. Zhenya Lindgardt M.B.A. · 71 employees · United States · https://www.sera.com